Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. large shareholder entities affiliated with Insight reported a combination of share conversions and sales. On June 16, 2026, they converted an aggregate 65,581 shares of Class B Common Stock into Class A Common Stock, then executed open-market sales of 65,581 Class A shares at an average price of $70.3596 per share through indirect holdings noted in the footnotes. Following these transactions, the reported Class A positions in the sale lines were reduced to zero, while significant Class B Common Stock positions remained outstanding as derivative securities.
Hinge Health, Inc. submitted a Form 144 notice concerning certain securities. The filing references 106,729 units tied to Series B Preferred Stock dated 07/03/2018 and lists 06/16/2026 alongside two numeric entries: 51,637,302.00 and 54,655,926. The excerpt also names Raymond James & Associates and includes the phrase Stock Conversion before IPO.
Hinge Health, Inc. notice of proposed sale of securities under Rule 144. The filing lists Common Class A and previously issued Series B Preferred Stock (noted as "Stock Conversion before IPO"), with a Series B quantity of 4,485,644 shown and transaction-related dates of 07/03/2018 and 06/16/2026.
Hinge Health, Inc. reported June transactions in which Bessemer Venture Partners funds sold Class A Common Stock. On June 10, 2026, Bessemer Venture Partners X L.P. sold 15,619 shares and Bessemer Venture Partners X Institutional L.P. sold 14,662 shares at a weighted average price of $65.20, in multiple trades between $65.00 and $65.88. On June 11, 2026, the same funds sold 30,042 and 28,201 shares, respectively, at a weighted average price of $66.02, with prices from $65.55 to $66.45. On June 12, 2026, they sold 8,694 and 8,161 shares, respectively, at a weighted average price of $65.24, in trades between $65.00 and $66.00. Director Robinson Elliott is a partner at Bessemer Venture Partners and reports an indirect, passive economic interest in these holdings and expressly disclaims beneficial ownership except to the extent of any pecuniary interest.
Hinge Health announced it will host its first Investor Day on June 10, 2026, alongside a significant raise to its 2026 outlook. For Q2 2026, the company now expects revenue between $200 million and $202 million, with year-over-year growth of 45% at the midpoint and non-GAAP operating margin of 25%.
For full year 2026, Hinge Health now guides to revenue of $818 million to $824 million, implying 40% year-over-year growth at the midpoint. Non-GAAP income from operations is projected between $217 million and $227 million, for a non-GAAP operating margin of 27% at the midpoint.
Hinge Health, Inc. Schedule 13G/A amendment reports that Atomico Advisors IV, Ltd., together with affiliated Atomico IV entities, beneficially owns 2,300,000 shares of Class A Common Stock, representing 2.88% of the company’s combined capital stock. The filing states the 79,961,966 total shares outstanding as of April 30, 2026 and discloses that portions of the holdings are subject to share collar contracts dated December 8, 2025.
Hinge Health, Inc. executive chairman and co‑founder Gabriel M.I. Mecklenburg reported an exercise‑and‑sell style transaction involving the company’s dual‑class shares. He converted 50,000 shares of Class B common stock into Class A common stock and then sold 50,000 Class A shares in open‑market transactions.
The weighted average sale price was about $65.53 per share, with individual trades ranging from $65.00 to $65.92, executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 1, 2025. Following the sales, he reported no directly held Class A shares, while continuing to hold substantial Class B interests directly and indirectly through a family trust and a GRAT, each convertible one‑for‑one into Class A shares. The filing also notes 944,250 performance stock units held by the reporting person are excluded from these share counts.
Hinge Health, Inc. director Leslie Kristina M received an equity compensation award in the form of restricted stock units. On June 3, 2026, she was granted 3,837 shares of Class A Common Stock at a reference value of $52.12 per share.
The award consists of 3,837 restricted stock units (RSUs) issued under the company’s Non-Employee Director Compensation Program for board service. These RSUs vest according to the award’s terms, and each RSU converts into one share of Class A Common Stock upon settlement. Following this grant, Leslie Kristina M directly owns 31,587 shares of Class A Common Stock.